Published • loading... • Updated
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
Throsby, a Monash University graduate and former Genmab chief scientific officer, will focus on clinical development and the company’s antibody platform.
Summary by Enid News & Eagle
6 Articles
6 Articles
ATB Therapeutics Names Mark Throsby CEO to Drive Next Growth Phase
ATB Therapeutics, a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, on May 19th announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. Mark Throsby has served as Executive Chairman and Chief Scientific Officer…
Coverage Details
Total News Sources6
Leaning Left2Leaning Right0Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 40%
C 60%
Factuality
To view factuality data please Upgrade to Premium
